ADIL
Adial Pharmaceuticals, Inc.0.2640
-0.0102-3.72%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.04MP/E (TTM)
-Basic EPS (TTM)
-0.60Dividend Yield
0%Recent Filings
8-K
Adial cuts losses, advances AD04
Adial Pharmaceuticals reported FY2025 net loss of $8.0 million, down from $13.2 million in 2024, with cash at $5.9 million funding operations into H2 2026. Key wins included positive AD04-103 PK results, FDA-aligned EOP2 meeting, and U.S. manufacturing pacts. Cash burn slashed. Signed framework with Molteni for Europe commercialization, eyeing ~$60 million potential.
10-K
FY2025 results
Adial narrowed FY2025 net loss to $8.0M from $13.2M in FY2024, driven by $4.5M non-cash warrant inducement expense last year and 19% R&D cut to $2.6M amid clinical pauses—yet cash burn eased to $6.5M. Q4 momentum built on FDA's EOP2 alignment for AD04's adaptive Phase 3 design targeting biomarker-positive AUD patients, confirming zero heavy drinking days endpoint after ONWARD's 79% heavy drinker reduction. No revenue; $5.9M cash funds into H2 2026, with $8.5M raised via warrant exercises and offerings. Molteni framework eyes Europe royalties post-approval. Cash won't last. Substantial doubt lingers on funding Phase 3.
8-K
AD04 Europe framework deal
Adial Pharmaceuticals inked a collaboration framework with Molteni Farmaceutici on March 3, 2026, for exclusive AD04 commercialization in Europe, pending definitive agreement. It anticipates upfront payment, development milestones, and tiered royalties from high single to low double digits, with nearly $60 million potential aggregate value. Framework grants Molteni exclusivity for due diligence. Deal validates AD04's path, but requires final execution.
8-K
Regains Nasdaq compliance
Adial Pharmaceuticals regained Nasdaq compliance on February 23, 2026, after its common stock closed at $1.00 or higher for 10 straight business days from February 6-20. Nasdaq closed the matter. CEO Cary Claiborne called it a key milestone while advancing AD04 toward Phase 3. Advanced partnering talks underway.
8-K
1-for-25 reverse split executed
Adial Pharmaceuticals executed a 1-for-25 reverse stock split, effective February 5, 2026, slashing outstanding shares from 27.8 million to 1.1 million. This aims to boost the bid price for Nasdaq compliance and attract more investors. Trading resumes split-adjusted on February 6. No assurance it sustains the $1 minimum.
ACET
Adicet Bio, Inc.
0.47-0.03
ADAG
Adagene Inc.
1.90+0.23
ADXN
Addex Therapeutics Ltd
7.56+0.55
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANL
Adlai Nortye Ltd.
1.64+0.15
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ATHE
Alterity Therapeutics Limited
3.07+0.06
IGC
IGC Pharma, Inc.
0.34+0.00
LBRX
LB Pharmaceuticals Inc
19.82-0.04
TIL
Instil Bio, Inc.
11.25+0.13